Newsletter
DUBLIN, Ireland: Demographic data shows that populations around the world are becoming increasingly older, which leaves dental professionals with a high number of compromised patients and risk factors when it comes to dental implant treatment. Therefore, the demand for products that might reduce the need for invasive grafting procedures is high.
Straumann intends to meet the demand by broadening its Roxolid SLActive implant portfolio. At the EAO congress in Dublin, the global market leader in dental implantology is currently introducing its unique dental implant material Roxolid for all diameters and all implant lines for the first time. Moreover, the company has announced the launch of a new 4 mm short Roxolid implant line to be used in clinical cases with limited vertical space, as with severely atrophied jawbone.
All Roxolid SLActive implants feature the new Loxim transfer piece and are covered by Straumann’s lifetime implant guarantee. The combination of the high mechanical strength of Roxolid with the excellent osseointegration properties of the hydrophilic SLActive surface now allows dental professionals to avoid guided bone regeneration procedures by choosing smaller implants, Straumann said.
Research has shown that the use of smaller diameters or shorter implant lengths can reduce the invasiveness of implant treatments and increase patient acceptance if invasive grafting procedures can be eliminated. Therefore, clinicians can reduce the treatment time, preserve vital peri-implant structures, decrease post-surgical complications, and gain new implant patients by offering products that seek to eliminate guided bone regeneration procedures. In these cases, patients can benefit from a less traumatic, less expensive and shorter treatment with a lifelong implant solution.
